 Kevin Messacar
Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterovirus Infections | 32 | 2025 | 173 | 11.040 |
Why?
| | Enterovirus D, Human | 21 | 2025 | 85 | 6.830 |
Why?
| | Myelitis | 25 | 2025 | 104 | 6.820 |
Why?
| | Central Nervous System Viral Diseases | 17 | 2025 | 76 | 5.510 |
Why?
| | Neuromuscular Diseases | 17 | 2025 | 129 | 5.220 |
Why?
| | Enterovirus | 14 | 2025 | 85 | 4.730 |
Why?
| | Meningitis | 8 | 2022 | 81 | 3.810 |
Why?
| | Encephalitis | 12 | 2022 | 136 | 3.750 |
Why?
| | Respiratory Tract Infections | 11 | 2025 | 384 | 3.360 |
Why?
| | Disease Outbreaks | 18 | 2025 | 417 | 3.220 |
Why?
| | Parechovirus | 4 | 2025 | 8 | 2.150 |
Why?
| | Anti-Infective Agents | 5 | 2023 | 236 | 2.110 |
Why?
| | Picornaviridae Infections | 4 | 2025 | 50 | 1.990 |
Why?
| | Multiplex Polymerase Chain Reaction | 4 | 2020 | 53 | 1.800 |
Why?
| | Nervous System Diseases | 5 | 2020 | 272 | 1.730 |
Why?
| | Paralysis | 5 | 2020 | 71 | 1.610 |
Why?
| | Hospitals, Pediatric | 5 | 2020 | 516 | 1.510 |
Why?
| | Molecular Diagnostic Techniques | 6 | 2020 | 102 | 1.400 |
Why?
| | Cerebrospinal Fluid | 6 | 2019 | 90 | 1.370 |
Why?
| | Central Nervous System Infections | 2 | 2022 | 35 | 1.350 |
Why?
| | Enterovirus A, Human | 2 | 2022 | 13 | 1.330 |
Why?
| | Child | 50 | 2025 | 21833 | 1.250 |
Why?
| | Antimicrobial Stewardship | 4 | 2023 | 117 | 1.240 |
Why?
| | Epidemiological Monitoring | 4 | 2025 | 65 | 1.200 |
Why?
| | Colorado | 21 | 2025 | 4515 | 1.160 |
Why?
| | Communicable Diseases | 4 | 2021 | 161 | 1.160 |
Why?
| | Herpesvirus 6, Human | 2 | 2019 | 14 | 1.070 |
Why?
| | Anti-Bacterial Agents | 6 | 2024 | 1799 | 1.010 |
Why?
| | Child, Preschool | 32 | 2025 | 11102 | 0.960 |
Why?
| | Viruses | 4 | 2023 | 161 | 0.930 |
Why?
| | Humans | 82 | 2025 | 137601 | 0.840 |
Why?
| | Infant | 25 | 2025 | 9539 | 0.760 |
Why?
| | Simplexvirus | 2 | 2020 | 82 | 0.750 |
Why?
| | Respiratory Tract Diseases | 1 | 2024 | 180 | 0.750 |
Why?
| | Influenza, Human | 3 | 2020 | 608 | 0.750 |
Why?
| | Nervous System Malformations | 1 | 2022 | 43 | 0.710 |
Why?
| | Brain Diseases | 2 | 2020 | 145 | 0.710 |
Why?
| | Sepsis | 2 | 2018 | 601 | 0.700 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 42 | 0.690 |
Why?
| | Virus Diseases | 1 | 2022 | 212 | 0.640 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2020 | 46 | 0.640 |
Why?
| | Acyclovir | 1 | 2020 | 95 | 0.640 |
Why?
| | Muscle Hypotonia | 2 | 2020 | 33 | 0.630 |
Why?
| | Exanthema Subitum | 1 | 2019 | 3 | 0.620 |
Why?
| | Drug Utilization | 2 | 2017 | 168 | 0.610 |
Why?
| | Hospitals, Teaching | 1 | 2019 | 114 | 0.610 |
Why?
| | Hepatitis | 1 | 2019 | 47 | 0.610 |
Why?
| | Taenia solium | 1 | 2018 | 5 | 0.600 |
Why?
| | Encephalitis, Viral | 2 | 2020 | 45 | 0.600 |
Why?
| | Neurocysticercosis | 1 | 2018 | 8 | 0.600 |
Why?
| | Meningoencephalitis | 2 | 2019 | 24 | 0.590 |
Why?
| | Abdomen | 1 | 2019 | 128 | 0.580 |
Why?
| | Gastroenteritis | 1 | 2019 | 68 | 0.580 |
Why?
| | Fluoxetine | 1 | 2018 | 55 | 0.570 |
Why?
| | Polymerase Chain Reaction | 6 | 2024 | 1047 | 0.570 |
Why?
| | Bacteriological Techniques | 1 | 2018 | 68 | 0.560 |
Why?
| | Diagnosis, Differential | 6 | 2019 | 1488 | 0.540 |
Why?
| | Retrospective Studies | 18 | 2024 | 15720 | 0.530 |
Why?
| | Metagenomics | 6 | 2023 | 177 | 0.530 |
Why?
| | Vaccines | 1 | 2022 | 402 | 0.510 |
Why?
| | Hospitalization | 7 | 2020 | 2197 | 0.510 |
Why?
| | Seizures | 1 | 2020 | 430 | 0.500 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 20 | 0.500 |
Why?
| | Bacterial Infections | 1 | 2018 | 244 | 0.490 |
Why?
| | Antiviral Agents | 2 | 2020 | 760 | 0.490 |
Why?
| | Analgesia, Epidural | 1 | 2016 | 33 | 0.490 |
Why?
| | Fever | 2 | 2019 | 306 | 0.480 |
Why?
| | Male | 35 | 2025 | 67690 | 0.480 |
Why?
| | Microbial Sensitivity Tests | 1 | 2016 | 346 | 0.470 |
Why?
| | Bacteria | 3 | 2023 | 867 | 0.470 |
Why?
| | Health Resources | 1 | 2016 | 124 | 0.450 |
Why?
| | Parotitis | 1 | 2014 | 6 | 0.430 |
Why?
| | Motor Neurons | 1 | 2016 | 229 | 0.430 |
Why?
| | Herpesviridae Infections | 1 | 2015 | 148 | 0.410 |
Why?
| | Respiratory Syncytial Virus, Human | 2 | 2025 | 73 | 0.410 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 803 | 0.410 |
Why?
| | United States | 16 | 2025 | 14925 | 0.400 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2025 | 125 | 0.390 |
Why?
| | Female | 32 | 2025 | 73359 | 0.390 |
Why?
| | Magnetic Resonance Imaging | 5 | 2020 | 3607 | 0.380 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2016 | 397 | 0.370 |
Why?
| | Pediatrics | 1 | 2019 | 1071 | 0.360 |
Why?
| | Infant, Newborn | 9 | 2019 | 6125 | 0.350 |
Why?
| | Referral and Consultation | 1 | 2017 | 794 | 0.350 |
Why?
| | High-Throughput Nucleotide Sequencing | 5 | 2023 | 541 | 0.350 |
Why?
| | Prospective Studies | 6 | 2025 | 7580 | 0.350 |
Why?
| | Quality Improvement | 1 | 2019 | 1180 | 0.350 |
Why?
| | Brain | 3 | 2018 | 2725 | 0.330 |
Why?
| | Meningitis, Aseptic | 2 | 2020 | 13 | 0.330 |
Why?
| | Seasons | 3 | 2019 | 537 | 0.330 |
Why?
| | Cohort Studies | 6 | 2024 | 5691 | 0.320 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1153 | 0.310 |
Why?
| | Internship and Residency | 1 | 2019 | 1172 | 0.300 |
Why?
| | Genome, Microbial | 2 | 2019 | 7 | 0.280 |
Why?
| | Adolescent | 17 | 2025 | 21435 | 0.260 |
Why?
| | Paramyxoviridae Infections | 1 | 2025 | 13 | 0.240 |
Why?
| | Metapneumovirus | 1 | 2025 | 16 | 0.240 |
Why?
| | Rhinovirus | 2 | 2017 | 57 | 0.220 |
Why?
| | Paraplegia | 2 | 2015 | 60 | 0.220 |
Why?
| | Sequence Analysis, DNA | 5 | 2023 | 826 | 0.220 |
Why?
| | Mycoplasma pneumoniae | 1 | 2024 | 54 | 0.220 |
Why?
| | Pleural Effusion | 1 | 2024 | 55 | 0.220 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2024 | 55 | 0.220 |
Why?
| | Acute Disease | 4 | 2019 | 1005 | 0.200 |
Why?
| | Time Factors | 4 | 2018 | 6818 | 0.200 |
Why?
| | Streptococcus pneumoniae | 1 | 2024 | 168 | 0.200 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 16 | 0.200 |
Why?
| | Canada | 3 | 2025 | 407 | 0.200 |
Why?
| | Arbovirus Infections | 2 | 2020 | 20 | 0.190 |
Why?
| | Community-Acquired Infections | 1 | 2024 | 171 | 0.190 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 65 | 0.190 |
Why?
| | Respiratory System | 1 | 2023 | 155 | 0.190 |
Why?
| | Pandemics | 4 | 2025 | 1627 | 0.190 |
Why?
| | Fungi | 1 | 2023 | 150 | 0.180 |
Why?
| | Uncertainty | 1 | 2022 | 129 | 0.180 |
Why?
| | Hashimoto Disease | 1 | 2021 | 12 | 0.180 |
Why?
| | Medical Oncology | 1 | 2023 | 301 | 0.170 |
Why?
| | Lung | 1 | 2014 | 4057 | 0.170 |
Why?
| | Brain Abscess | 1 | 2020 | 10 | 0.170 |
Why?
| | Esophageal Perforation | 1 | 2020 | 15 | 0.170 |
Why?
| | Esophageal Fistula | 1 | 2020 | 19 | 0.170 |
Why?
| | Antigens, Viral | 2 | 2019 | 179 | 0.170 |
Why?
| | Meningitis, Viral | 1 | 2020 | 20 | 0.170 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2020 | 21 | 0.160 |
Why?
| | Muscle Weakness | 1 | 2020 | 92 | 0.160 |
Why?
| | Confusion | 1 | 2020 | 29 | 0.160 |
Why?
| | Immunocompetence | 1 | 2019 | 42 | 0.150 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2019 | 24 | 0.150 |
Why?
| | Myelitis, Transverse | 1 | 2019 | 3 | 0.150 |
Why?
| | Seroepidemiologic Studies | 1 | 2019 | 163 | 0.150 |
Why?
| | Agammaglobulinemia | 1 | 2019 | 34 | 0.150 |
Why?
| | Foreign Bodies | 1 | 2020 | 105 | 0.150 |
Why?
| | Antibodies, Helminth | 1 | 2018 | 6 | 0.150 |
Why?
| | HIV Infections | 1 | 2014 | 2941 | 0.150 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2019 | 53 | 0.150 |
Why?
| | Meningitis, Bacterial | 1 | 2019 | 46 | 0.150 |
Why?
| | Body Fluids | 1 | 2018 | 69 | 0.140 |
Why?
| | Leukocyte Count | 1 | 2018 | 320 | 0.140 |
Why?
| | Arboviruses | 1 | 2017 | 14 | 0.140 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 14 | 0.140 |
Why?
| | Headache | 1 | 2018 | 147 | 0.140 |
Why?
| | Program Development | 1 | 2019 | 362 | 0.130 |
Why?
| | Refusal to Treat | 1 | 2017 | 16 | 0.130 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 111 | 0.130 |
Why?
| | Neuromyelitis Optica | 1 | 2019 | 134 | 0.130 |
Why?
| | Drug Utilization Review | 1 | 2017 | 55 | 0.130 |
Why?
| | Treatment Failure | 1 | 2018 | 346 | 0.130 |
Why?
| | Herpes Simplex | 1 | 2017 | 95 | 0.130 |
Why?
| | RNA | 1 | 2023 | 926 | 0.130 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1941 | 0.130 |
Why?
| | Densovirus | 1 | 2016 | 4 | 0.130 |
Why?
| | Prevalence | 2 | 2015 | 2735 | 0.130 |
Why?
| | Movement Disorders | 1 | 2017 | 64 | 0.130 |
Why?
| | Drug Resistance | 1 | 2017 | 145 | 0.130 |
Why?
| | Communicable Disease Control | 1 | 2017 | 83 | 0.130 |
Why?
| | Muscular Diseases | 1 | 2017 | 112 | 0.130 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2016 | 17 | 0.130 |
Why?
| | Encephalomyelitis | 1 | 2016 | 13 | 0.130 |
Why?
| | Electromyography | 2 | 2017 | 392 | 0.120 |
Why?
| | Eosinophilia | 1 | 2018 | 218 | 0.120 |
Why?
| | Balamuthia mandrillaris | 1 | 2015 | 4 | 0.120 |
Why?
| | Amebiasis | 1 | 2015 | 5 | 0.120 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1226 | 0.120 |
Why?
| | Genome, Mitochondrial | 1 | 2015 | 28 | 0.120 |
Why?
| | Early Diagnosis | 1 | 2016 | 237 | 0.120 |
Why?
| | Neoplasms | 2 | 2023 | 2691 | 0.120 |
Why?
| | North America | 1 | 2016 | 308 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2023 | 843 | 0.120 |
Why?
| | Program Evaluation | 1 | 2019 | 909 | 0.120 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2016 | 147 | 0.120 |
Why?
| | Treatment Outcome | 3 | 2019 | 10813 | 0.110 |
Why?
| | La Crosse virus | 1 | 2014 | 7 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2020 | 3550 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1089 | 0.110 |
Why?
| | Encephalitis, California | 1 | 2014 | 11 | 0.110 |
Why?
| | West Nile Fever | 1 | 2014 | 53 | 0.110 |
Why?
| | Hospitals | 1 | 2019 | 691 | 0.110 |
Why?
| | Kidney | 1 | 2021 | 1469 | 0.100 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 167 | 0.100 |
Why?
| | Adult | 6 | 2023 | 37910 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1038 | 0.100 |
Why?
| | Neuroimaging | 1 | 2014 | 261 | 0.100 |
Why?
| | Orthomyxoviridae | 1 | 2012 | 40 | 0.090 |
Why?
| | Temperature | 1 | 2015 | 664 | 0.090 |
Why?
| | Clinical Competence | 1 | 2019 | 1122 | 0.090 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 245 | 0.090 |
Why?
| | Critical Care | 1 | 2017 | 616 | 0.090 |
Why?
| | Models, Theoretical | 2 | 2025 | 578 | 0.090 |
Why?
| | Population Surveillance | 1 | 2014 | 479 | 0.090 |
Why?
| | Risk Assessment | 1 | 2019 | 3438 | 0.080 |
Why?
| | Risk Factors | 2 | 2020 | 10319 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5121 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2025 | 648 | 0.070 |
Why?
| | Animals | 3 | 2019 | 37088 | 0.070 |
Why?
| | Young Adult | 4 | 2019 | 13203 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1739 | 0.070 |
Why?
| | Quality of Life | 1 | 2018 | 2942 | 0.060 |
Why?
| | Models, Biological | 2 | 2025 | 1783 | 0.060 |
Why?
| | California | 2 | 2019 | 440 | 0.060 |
Why?
| | Scotland | 1 | 2025 | 18 | 0.060 |
Why?
| | Republic of Korea | 1 | 2025 | 39 | 0.060 |
Why?
| | Immunoglobulin G | 2 | 2019 | 902 | 0.060 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2024 | 47 | 0.050 |
Why?
| | Cluster Analysis | 2 | 2016 | 512 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2679 | 0.050 |
Why?
| | Pregnancy | 1 | 2016 | 6770 | 0.050 |
Why?
| | Computational Biology | 2 | 2019 | 649 | 0.050 |
Why?
| | Adenoviridae | 1 | 2023 | 198 | 0.050 |
Why?
| | Immunologic Surveillance | 1 | 2022 | 26 | 0.050 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 232 | 0.050 |
Why?
| | Phylogeny | 2 | 2016 | 1006 | 0.040 |
Why?
| | Spatio-Temporal Analysis | 1 | 2021 | 34 | 0.040 |
Why?
| | Africa, Western | 1 | 2020 | 21 | 0.040 |
Why?
| | Technology | 1 | 2021 | 93 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 293 | 0.040 |
Why?
| | Child, Hospitalized | 1 | 2020 | 53 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2020 | 130 | 0.040 |
Why?
| | Consciousness Disorders | 1 | 2019 | 20 | 0.040 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2019 | 11 | 0.040 |
Why?
| | Picornaviridae | 1 | 2019 | 20 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 347 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2836 | 0.030 |
Why?
| | Global Health | 1 | 2020 | 382 | 0.030 |
Why?
| | Neural Conduction | 1 | 2017 | 89 | 0.030 |
Why?
| | Atrophy | 1 | 2017 | 188 | 0.030 |
Why?
| | Sequence Homology | 1 | 2016 | 43 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 451 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 16 | 0.030 |
Why?
| | Guatemala | 1 | 2017 | 327 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2016 | 132 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2023 | 1073 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 672 | 0.030 |
Why?
| | Aftercare | 1 | 2017 | 207 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 688 | 0.030 |
Why?
| | Genome, Viral | 1 | 2016 | 222 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2016 | 262 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 368 | 0.030 |
Why?
| | Cost of Illness | 1 | 2016 | 308 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 96 | 0.030 |
Why?
| | Length of Stay | 1 | 2019 | 1210 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 403 | 0.030 |
Why?
| | Survival Rate | 1 | 2017 | 1906 | 0.020 |
Why?
| | Incidence | 1 | 2019 | 2805 | 0.020 |
Why?
| | Middle Aged | 3 | 2019 | 33441 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2076 | 0.020 |
Why?
| | Autoantibodies | 1 | 2019 | 1454 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3287 | 0.020 |
Why?
| | Critical Illness | 1 | 2016 | 805 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 3966 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2840 | 0.020 |
Why?
| | Aged | 2 | 2019 | 23938 | 0.020 |
Why?
|
|
Messacar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|